NVO
XNYSNOVO-NORDISK A/S-SPONS ADR
6 news · 90d
6 news · vs previous 7d (—)
Sentiment scores computed by AI · Not investment advice.
News · 6
How did the price react? →- Yahoo4/24/2026, 3:05:29 PMHow Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story
Hims & Hers Health has expanded its platform to allow clinicians to prescribe Eli Lilly GLP-1 treatments (Zepbound vials, KwikPen, and Foundayo) fulfilled via LillyDirect, while also broadening access to Novo Nordisk therapies. The company additionally acquired a facility to strengthen peptide capabilities ahead of an FDA review on compounding. These moves deepen HIMS's role in prescription weight management and could materially shift its product mix.
AI-generated content for informational purposes only. Not investment advice.
Sentiment 0.55Relevance 45% - Yahoo4/24/2026, 3:00:00 PMEli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.
AI-generated content for informational purposes only. Not investment advice.
Sentiment -0.10Relevance 35% - Yahoo4/24/2026, 2:18:00 PMSpherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment
Spherix Global Insights released a report finding high adoption rates among physicians for both Eli Lilly's LillyDirect and Novo Nordisk's NovoCare direct-to-patient platforms for obesity treatment, though workflow differences are driving a specialty-based split in platform preference. LillyDirect launched in January 2024 and NovoCare in March 2025, with both now increasingly integrated into physician workflows. The report highlights evolving competitive dynamics in the direct-to-patient obesity drug distribution channel.
AI-generated content for informational purposes only. Not investment advice.
Sentiment 0.10Relevance 60% - Yahoo4/24/2026, 2:10:06 PMBattle Of The Weight-Loss Pills Continues With A Shocking Twist
Eli Lilly's stock declined after data showed Novo Nordisk's oral Wegovy outperforming Lilly's newly launched weight-loss pill, Foundayo. The comparison highlights intensifying competition in the oral GLP-1 weight-loss drug market. Both companies are vying for market share in the rapidly growing obesity treatment segment.
AI-generated content for informational purposes only. Not investment advice.
Sentiment -0.60Relevance 85% - Yahoo4/24/2026, 1:37:23 PMLilly’s New Obesity Pill Off to Slow Start in Race With Novo
Eli Lilly's new oral weight-loss drug Foundayo is showing slow early prescription uptake, according to new prescription data. The sluggish start highlights the challenge Lilly faces in competing with Novo Nordisk in the obesity drug market. The data represents an early indicator only and does not reflect long-term commercial trajectory.
AI-generated content for informational purposes only. Not investment advice.
Sentiment -0.45Relevance 60% - Yahoo4/24/2026, 10:46:00 AMLilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Eli Lilly shares fell as its obesity drug Foundayo showed a weaker early commercial trajectory compared to oral Wegovy, while Novo Nordisk shares climbed on the contrast. Regeneron announced a drug pricing deal, and two unspecified companies disclosed leadership changes. The FDA also announced plans to issue vouchers related to psychedelic treatments.
AI-generated content for informational purposes only. Not investment advice.
Sentiment -0.30Relevance 60%